The Pharma Letter2h
Viatris faces FDA import restrictions at Indian facility
Viatris faces US FDA regulatory action on its Indore, India facility, with a warning letter and import alert restricting 11 ...
The Pharma Letter3h
Positive Phase III trials results with BMS’ Sotyktu
US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055 ...
The Pharma Letter6h
Sumitomo gains FDA approval of Gemtesa for OAB
The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...
The Pharma Letter5h
FDA approves first generic of Victoza
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza ...
The Pharma Letter7h
Traws Pharma soars as it advances H5N1 bird flu treatment
USA-based clinical-stage biopharma Traws Pharma saw its shares leap more than 150% to $12.57 as it announced progress in the ...
The Pharma Letter7h
RAPT obtains worldwide rights ex-China to Jemincare MAb
USA-based immunology company RAPT Therapeutics has entered into an exclusive license agreement with Shanghai Jemincare ...
The Pharma Letter17h
Aficamten attracts more interest as Sanofi buys China rights
Cytokinetics (Nasdaq: CYTK) has sold Sanofi (Euronext: SAN) exclusive rights to develop and commercialize aficamten in China.
The Pharma Letter17h
Poxel Pharma
Poxel is a biopharmaceutical company developing drugs for metabolic diseases, with a focus on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono. Poxel is focsed on ...